Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.53 |
| ▸ | TP53 | P04637 | 4/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | KLK7 | P49862 | 1/20 | 0.43 |
| ▸ | SCD | O00767 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27635999 | 0.94 | MAPK14 (0.50) | MAPK14TP53MAPK11MAPTDHODH | |
| SCHEMBL3347281 | 0.93 | MAPT (0.49) | MAPK14TP53MAPK11ADORA3MAPT | |
| SCHEMBL3313848 | 0.93 | MAPK14 (0.47) | MAPK14TP53MAPK11MAPT | |
| SCHEMBL3346606 | 0.93 | MAPT (0.49) | MAPK14TP53MAPK11ADORA1ADORA3 | |
| SCHEMBL3349382 | 0.92 | MAPK14 (0.55) | MAPK14TP53MAPK11MAPTNPC1 | |
| SCHEMBL3345525 | 0.92 | MAPK14 (0.49) | MAPK14TP53MAPK11MAPT | |
| SCHEMBL3346424 | 0.92 | MAPK14 (0.46) | MAPK14TP53MAPK11MAPT | |
| SCHEMBL3352426 | 0.92 | MAPK14 (0.49) | MAPK14TP53MAPK11MAPTRAB9A | |
| SCHEMBL3351894 | 0.91 | MAPK14 (0.52) | MAPK14TP53MAPK11MAPT | |
| SCHEMBL3319041 | 0.91 | MAPK14 (0.49) | MAPK14TP53MAPK11MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652044-B2 | P-38 inhibitors | NOVARTIS A.G. (CH) | 2010-01-26 | — | — | US | claimed |
| US-20100004298-A1 | P-38 INHIBITORS | DONG QING | 2010-01-07 | — | — | US | claimed |
| EP-1635824-B1 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | NOVARTIS AG (CH) | 2009-08-19 | — | — | EP | claimed |
| US-20040254236-A1 | P-38 inhibitors | NOVARTIS AG (CH) | 2004-12-16 | — | — | US | claimed |
| US-7652044-B2 | P-38 inhibitors | NOVARTIS A.G. (CH) | 2010-01-26 | — | — | US | disclosed |
| US-7652044-B2 | P-38 inhibitors | NOVARTIS A.G. (CH) | 2010-01-26 | — | — | US | disclosed |
| US-7652044-B2 | P-38 inhibitors | NOVARTIS A.G. (CH) | 2010-01-26 | — | — | US | disclosed |
| US-20100004298-A1 | P-38 INHIBITORS | DONG QING | 2010-01-07 | — | — | US | disclosed |
| US-20100004298-A1 | P-38 INHIBITORS | DONG QING | 2010-01-07 | — | — | US | disclosed |
| EP-1635824-B1 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | NOVARTIS AG (CH) | 2009-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004298-A1 | P-38 INHIBITORS | MAPK8, MAPK1, MAP3K8 | MAPK14 21/4885TP53 552/4885MAPK11 38/4885 |
| US-20040254236-A1 | P-38 inhibitors | MAPK8, MAP3K8, MAPK1 | MAPK14 12/4885TP53 474/4885MAPK11 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.